PolarityTE: Q1 2023 Earnings Estimate for PolarityTE, Inc. (NASDAQ:PTE) Issued By Northland Capmk

PolarityTE, Inc. ( NASDAQ:PTE - Get Rating ) - Investment analysts at Northland Capmk issued their Q1 2023 EPS estimates for PolarityTE in a research note issued to investors on Wednesday, March 29th. Northland Capmk analyst C. Byrnes forecasts that the company will earn ($0.69) per share for the quarter. The consensus estimate for PolarityTE's current full-year earnings is ($4.60) per share. Northland Capmk also issued estimates for PolarityTE's Q2 2023 earnings at ($0.55) EPS, Q3 2023 earnings at ($0.47) EPS and Q4 2023 earnings at ($0.46) EPS. Separately, Northland Securities reduced their target price on PolarityTE from $1.25 to $1.00 and set an "outperform" rating for the company in a report on Wednesday, December 28th. A number of hedge funds have recently bought and sold shares of PTE. Prudential Financial Inc. bought a new stake in shares of PolarityTE in the second quarter valued at approximately $25,000. Renaissance Technologies LLC boosted its holdings in PolarityTE by 55.2% in the 3rd quarter. Renaissance Technologies LLC now owns 67,222 shares of the company's stock valued at $58,000 after purchasing an additional 23,900 shares during the period. First Republic Investment Management Inc. boosted its holdings in PolarityTE by 554.6% in the 1st quarter. First Republic Investment Management Inc. now owns 108,662 shares of the company's stock valued at $27,000 after purchasing an additional 92,062 shares during the period. Finally, LPL Financial LLC acquired a new stake in PolarityTE in the 4th quarter worth $189,000. 11.75% of the stock is currently owned by institutional investors. ( Get Rating ) PolarityTE, Inc is a biotechnology company developing and commercializing regenerative tissue products and biomaterials. The firm products include SkinTE Cryo, SkinTE POC, PTE 11000, OsteoTE and Real Time Assistant. Its SkinTE product is commercially available for the repair, reconstruction, replacement, and supplementation of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. Receive News & Ratings for PolarityTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolarityTE and related companies with MarketBeat.com's FREE daily email newsletter .